Skip to content

Study · Case report or series · n = 1 · 2025

1 result

A Case Report of Bezoar-Induced Small Bowel Obstruction: A Potential Surgical Complication of Semaglutide.

Keng C, Thor SM, Balasubramaniam R, Pretorius F

Cureus19 Dec 2025

PMID41431486 (opens in a new tab)PMCIDPMC12718217 (opens in a new tab)DOI10.7759/cureus.99664 (opens in a new tab)PepBankPUB-41431486
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Bezoars are an uncommon but recognised cause of small bowel obstruction (SBO) and are difficult to differentiate preoperatively from other aetiologies. We report a rare case of acute SBO due to a bezoar in a 65-year-old woman who had been on semaglutide, a Glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight loss. She presented with a four-day history of abdominal pain, distension, nausea, and vomiting. Imaging confirmed SBO. Following unsuccessful nonoperative management, she underwent diagnostic laparoscopy and laparoscopic resection of a jejunal segment containing a large phytobezoar. We postulated that semaglutide-induced gastroparesis and slow intestinal transit may have contributed to bezoar formation and subsequent bowel obstruction. This case highlights a rare but important surgical adverse effect, particularly in patients receiving GLP-1 receptor agonists who present with bowel obstruction.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 65-year-old woman taking semaglutide for weight loss, acute small bowel obstruction due to a phytobezoar occurred and needed laparoscopic resection of a jejunal segment.

    In plain wordsA 65-year-old woman taking semaglutide for weight loss had a bowel blockage from a bezoar and needed surgery; the report cannot prove semaglutide caused it.

    Peptide
    Semaglutide
    Outcome
    Not applicableBezoar-induced small bowel obstruction
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We report a rare case of acute SBO due to a bezoar in a 65-year-old woman who had been on semaglutide, a Glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight loss.
    1 context sentence
    Summary · context
    Following unsuccessful nonoperative management, she underwent diagnostic laparoscopy and laparoscopic resection of a jejunal segment containing a large phytobezoar.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.